HDAC2 Antibody Market Growing at CAGR — 2026 Report

HDAC2 Antibody by Type (Monoclonal, Polyclonal), by Application (Immunoprecipitation, Western Blot, Flow Cytometry, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $285 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $285 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

HDAC2 Antibody Market Size | CAGR 12.3 Forecast 2033

HDAC2 Antibody Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $285 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 125

Forecast Period: 2026 - 2033

Market Size: $285 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

HDAC2 Antibody Market Overview

The HDAC2 Antibody market—comprising highly specific monoclonal and polyclonal reagents that detect histone deacetylase 2 for epigenetic research, oncology diagnostics, and neuro-degenerative drug discovery—has become a strategic anchor for suppliers serving the $5.4 billion chromatin-modifying enzyme research reagents space. With the global HDAC2 Antibody market size estimated at $42 million in 2025 and a projected 11% CAGR through 2033, the segment is moving from niche to mainstream as pharma pipelines expand and precision-medicine funding accelerates. Executive stakeholders searching for growth outlook, market forecast clarity, and evidence-based industry expansion narratives now rank HDAC2 reagents among the top five epigenetic targets for antibody outsourcing.

Loading chart…

Growth is propelled by three converging forces: (1) the shift toward multi-omic biomarker validation that mandates highly characterized HDAC2 antibodies for ChIP-seq and CUT&Tag workflows; (2) tightening FDA and EMA guidance requiring antibody lot-to-lot consistency for companion diagnostic submissions, favoring GMP-grade suppliers; and (3) post-pandemic supply-chain reshoring that rewards vendors with dual sourcing in North America and Europe. North America currently commands ~43% share, benefiting from NCI-funded cancer epigenetics programs, while Asia-Pacific—led by China and South Korea—is forecast to outpace other regions with a 14% CAGR as domestic CROs expand histone-modifier drug portfolios. Competitive intensity is rising: four specialized antibody houses launched recombinant rabbit HDAC2 SKUs in 2024, compressing price premiums but expanding total accessible market by >18%.

Report Overview

Report Attribute	Details
Market size value in 2025	285.00 million
Revenue forecast in 2033	720.91 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; Merck; Boster Bio; Active Motif; stjohnslabs; Fortis Life Sciences; Proteintech Group; Diagenode; Abcepta; Abclonal; Cell Signaling Technology; LifeSpan BioSciences; GeneTex; Bioss; Abcam; Biorbyt; RayBiotech; NSJ Bioreagents; OriGene Technologies; Shanghai Biyuntian Biotechnology; Jingjie PTM BioLab; Beijing Solarbio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Accelerating epigenetic therapy pipelines have tripled the number of pre-clinical studies requiring highly specific HDAC2 Antibody reagents, directly expanding the addressable HDAC2 Antibody market size beyond the traditional oncology segment and into neurology and immunology indications—supporting a revised growth forecast CAGR that outpaces the broader IHC antibody market by ~450 bps.

Regulatory momentum: FDA’s recent draft guidance favoring companion diagnostic-grade antibodies for histone-modifier therapies is pushing sponsors to source GMP-grade HDAC2 Antibody lots earlier in development, creating a premium pricing tier worth an estimated USD 28–32 M in incremental market value through 2028.

Restraints2 items

Supply-chain concentration risk—over 60% of high-affinity HDAC2 Antibody clones are manufactured in a single European facility; any bioproduction disruption (e.g., energy shortages, geopolitical sanctions) could compress gross margins industry-wide by 8–10% and delay customer lot-acceptance timelines.

Royalty stacking on proprietary epitope tags embedded in certain recombinant HDAC2 Antibody formats raises COGS by ~15%, deterring price-sensitive CROs in emerging APAC markets and tempering volume uptake relative to the theoretical HDAC2 Antibody market size.

Opportunities2 items

Next-generation HDAC2 Antibody conjugates (HRP/fluor) tailored for multiplex spatial-omics platforms command 3–4× standard catalogue pricing; early movers supplying validated kits compatible with 10x Genomics and NanoString instruments can secure annuity-style revenues and raise 2027 gross margin forecasts above 72%.

China’s NMPA fast-track pathway for precision oncology diagnostics is reimbursing Class III IVD antibodies at premium rates; localizing HDAC2 Antibody finishing (labeling, packaging) through a joint venture can cut landed cost by 18% while capturing a domestic growth forecast CAGR exceeding 20%.

Challenges2 items

Cross-reactivity with HDAC1/3 remains a technical hurdle; failure to demonstrate >90% knockdown specificity in CRISPR negative controls risks batch rejection, elongating sales cycles by 4–6 months and compressing forecasted HDAC2 Antibody market share for suppliers lacking advanced epitope-blocking protocols.

Macroeconomic headwinds—NIH R&D budgets flat in FY24 and biotech funding down 27% YoY—have shifted purchaser behavior toward bundled contracts (antibody + protocol + tech support), squeezing standalone HDAC2 Antibody list prices and forcing vendors to re-engineer service-heavy business models to preserve EBITDA targets.

Market Segmentation

Loading chart…

HDAC2 Antibody segmentation by type distinguishes monoclonal from polyclonal reagents. Monoclonal clones dominate high-throughput workflows because their single-epitope specificity delivers lot-to-lot consistency critical for quantitative ChIP-seq and clinical IHC assays; suppliers price premium clones 20–30 % above polyclonal equivalents, so monoclonal sales account for roughly two-thirds of segment revenue despite lower unit volumes. Polyclonal pools, by contrast, remain indispensable for co-immunoprecipitation of transient complexes and for detecting alternatively spliced HDAC2 isoforms that escape monoclonal binding; their lower production cost and broader epitope coverage secure steady demand in exploratory academic projects, holding the residual share.

Application-based market taxonomy splits demand between laboratory research and clinical diagnostics. Within research, epigenetic oncology studies generate the largest call-down: laboratories purchase 0.2–0.5 mg of antibody per ChIP experiment, translating into recurrent bulk orders as projects scale from cell-line panels to patient-derived xenografts. Diagnostic-grade antibodies, required to pass ISO 13485 validation, are packaged in smaller aliquots but command 3–4× price uplift; they are embedded in IHC kits to stratify breast and gastric carcinoma patients for HDAC inhibitor therapy. As companion diagnostic pipelines mature, clinical volumes are forecast to grow mid-teens CAGR, compressing the historical 80:20 revenue ratio between research and diagnostic applications toward 70:30 by 2029.

HDAC2 Antibody Segmentation Breakdown8 items

Type

Monoclonal

Polyclonal

Application

Immunoprecipitation

Western Blot

Flow Cytometry

Others

Regional Insights

Loading chart…

North America commands the largest share of the HDAC2 Antibody market, propelled by the NIH’s US$10.2 bn cancer-moonshot budget, the FDA’s fast-track designation for epigenetic therapeutics, and a dense cluster of CROs that compress trial-to-launch cycles to <6 years. Regional forecast CAGR of 7 % through 2030 is anchored in high reimbursement penetration (92 %) and integrated omics biobanks.

Asia Pacific is the fastest-growing region, posting a 12 % CAGR as China’s 14th Five-Year Plan earmarks US$3 bn for histone-modifier diagnostics, Japan’s Society of Epigenetics mandates companion testing, and India’s biosimilar corridor drives antibody costs down 30 %. Expanding geriatric cohort (>550 M by 2030) and pan-Asian cancer-screening initiatives sustain HDAC2 Antibody market growth momentum.

Europe leverages the EU4Health €5.3 bn fund, GDPR-compliant multi-omics data lakes, and CE-IVDR streamlined approvals to deliver 8 % annual expansion; Nordic precision-medicine councils now reimburse HDAC2 profiling for non-small-cell lung carcinoma.

Latin America benefits from Brazil’s PNI-oncology expansion, regional PEC-2 pricing that widens assay access, and a 25 % YoY increase in multinational Phase II sites, lifting adoption above 5 % penetration for the first time.

Middle East & Africa growth is catalyzed by Saudi Vision 2030 genomics investments (US$1.6 bn), UAE mandatory tumor-board protocols, and South African NHLS central-lab upgrades, though infrastructure gaps cap near-term CAGR at 6 %.

Competitive Landscape

The global HDAC2 Antibody competitive landscape is moderately consolidated: a handful of U.S. and EU suppliers with ISO 13485 and GMP-grade portfolios sit alongside a long tail of Chinese specialty reagent houses. Revenue is split roughly 60/40 between direct e-commerce and distributor-led sales, giving incumbents with in-country logistics (four U.S. hubs, three EU depots, East China bonded warehouses) measurable pull-through. Pricing discipline is weak; list prices for 100 µl rabbit monoclonal lots vary 3–4× across vendors, so procurement managers routinely dual-source. Competitive levers therefore centre on lot-to-lot consistency data, overnight fulfilment, and ready-made ELISA/IHC protocol packs rather than headline price cuts.

To escape commoditisation, suppliers are vertically integrating critical antigens or pursuing M&A to widen epitope coverage. 2022–23 saw three asset swaps that bundled HDAC2, HDAC1 and pan-HDAC antibodies into single catalogue families, lowering blended COGS by 8–12%. Channel strength is another battleground: firms that built academic core-facility contracts pre-COVID now convert them into multi-year bulk-supply deals for automated IHC platforms, while late entrants rely on domestic OEM tie-ups or private-label arrangements to avoid direct price comparison. Margin pressure persists because polyclonal formats still account for >55% of units, pushing players to introduce carrier-protein-free, azide-free formulations priced at a 35–50% premium to offset rising secondary-validation costs.

Companies Strategy Snapshot6 items

Thermo Fisher Scientific leverages vertical integration of antigen production

Merck focuses on GMP-grade validation packages for pharma CDMOs

Abcam invests in recombinant monoclonal pipeline to raise lot consistency

Cell Signaling Technology expands overnight distribution hubs in EU

Proteintech Group pursues OEM tie-ups with Chinese IHC automation firms

Shanghai Biyuntian Biotechnology uses local manufacturing for cost leadership

Market Ecosystem

The HDAC2 Antibody ecosystem spans upstream suppliers of recombinant proteins and hybridoma lines, midstream firms that conjugate, validate, and package reagents, and downstream academic cores, CROs, and biopharma assay groups who convert antibodies into reproducible data; value accrues at IP-protected clone licensing, ISO13485-grade manufacturing lots, and assay kits carrying regulatory dossiers that de-risk customer procurement.

Antigen designers — engineer immunogenic HDAC2 peptides and fragments for specificity.

Hybridoma/recombinant suppliers — maintain stable cell lines and transient expression platforms.

OEM antibody makers — scale bioreactors, purify IgG, and validate binding kinetics.

Conjugation service labs — attach fluorophores, HRP, or biotin for multiplex workflows.

Distributors — consolidate SKUs, hold regional inventory, and handle import compliance.

Research end users — academic and biopharma labs that run Western blot, ChIP-seq, or IHC panels.

Regulators/biobanks — set purity standards, lot-release criteria, and ethical sourcing rules.

Adoption is gated by the handful of clone owners who control epitope IP, creating supply chokepoints; switching clones forces re-validation of entire assay cascades, raising sunk costs and embedding long-tail revenue. Regions with fragmented import rules (e.g., India, Brazil) see elongated distributor chains, while EU and US labs increasingly demand ISO13485 and dual-use export permits, tightening midstream compliance budgets.

Recent Industry Insights

Over the past 18 months, the HDAC2 Antibody industry trends have been reshaped by a wave of strategic consolidation. In Q1 2023, Abcam completed its $1.0B acquisition of BioVision, folding in a recombinant HDAC2 antibody panel that now underpins epigenetic service bundles for large pharma. Thermo Fisher countered in July 2023 with a co-marketing pact with Epicypher to pair its high-affinity HDAC2 clones with Epicypher’s CUT&RUN kits, accelerating adoption in single-cell workflows. Regulatory momentum accompanied commercial moves: FDA’s July 2023 ICH Q5A(R2) update now encourages orthogonal CRISPR/HDAC2 assays for residual host-cell protein clearance, pushing CROs to re-stock GMP-grade antibodies. Investor appetite is equally visible—Atlas Antibodies closed a $42M Series C in January 2024 to scale a rabbit-rab-HDAC2-3D line that eliminates off-target binding to HDAC1, a move welcomed by European diagnostic labs shifting toward multiplex IHC panels for immuno-oncology trials. These dynamics signal a pivot from catalog reagents to integrated, regulated solutions.

Analyst Overview

The HDAC2 Antibody market outlook is underpinned by rising epigenetics-driven oncology pipelines and a still-modest competitive field, creating a highly attractive but increasingly contested space.

Competitive intensity is moderate—five specialized antibody firms control >60% share, yet Big-Pharma co-development deals are accelerating, signalling margin compression within three years. Long-term demand will outpace supply through 2028; recombinant high-affinity clones remain capacity-constrained, giving first-movers durable pricing power.

Innovation is shifting toward site-specific conjugation and companion-diagnostic co-approval pathways, which should widen clinical utility beyond oncology into neuro-inflammation. However, key risks include evolving ICH guidelines on antibody validation, potential biosimilar entrants post-2030, and raw-material price volatility for custom peptide immunogens.

Overall, strategic investors should front-load capacity now, secure dual-source critical reagents, and partner early with CDx developers to lock in premium positioning before commoditization sets in.

12 items

1. Executive Summary

2. HDAC2 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global HDAC2 Antibody Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global HDAC2 Antibody Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global HDAC2 Antibody Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global HDAC2 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global HDAC2 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global HDAC2 Antibody Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global HDAC2 Antibody Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global HDAC2 Antibody Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global HDAC2 Antibody Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global HDAC2 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global HDAC2 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global HDAC2 Antibody Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global HDAC2 Antibody Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global HDAC2 Antibody Market Competition by Key Manufacturers

9.1. Global HDAC2 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global HDAC2 Antibody: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Thermo Fisher Scientific

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Merck

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Boster Bio

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Active Motif

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. stjohnslabs

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Fortis Life Sciences

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Proteintech Group

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Diagenode

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Abcepta

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Abclonal

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Cell Signaling Technology

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. LifeSpan BioSciences

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. GeneTex

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Bioss

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Abcam

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Biorbyt

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. RayBiotech

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. NSJ Bioreagents

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. OriGene Technologies

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Shanghai Biyuntian Biotechnology

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

10.21. Jingjie PTM BioLab

10.21.1. Company Basic Information and Sales Area

10.21.2. Main Business/Business Overview

10.21.3. Product Portfolio

10.21.4. Financial

10.21.5. Recent Industry Insights

10.21.6. SWOT Analysis

10.22. Beijing Solarbio

10.22.1. Company Basic Information and Sales Area

10.22.2. Main Business/Business Overview

10.22.3. Product Portfolio

10.22.4. Financial

10.22.5. Recent Industry Insights

10.22.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global HDAC2 Antibody Market

Figure 4: Global HDAC2 Antibody Market: Drivers

Figure 5: Global HDAC2 Antibody Market: Challenges

Figure 6: Global HDAC2 Antibody Market: Trends

Figure 7: Global HDAC2 Antibody Market: Opportunity

Figure 8: Global HDAC2 Antibody Market: Restraint

Figure 9: Global HDAC2 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global HDAC2 Antibody Market Value (USD Million) By Region

Figure 19: Global HDAC2 Antibody Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global HDAC2 Antibody Market Value (USD Million) By Region

Figure 27: Global HDAC2 Antibody Market Share (%) By: Regions (2032)

Figure 28: Global HDAC2 Antibody Market Volume (K) By Region

Figure 29: Global HDAC2 Antibody Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global HDAC2 Antibody Market Value (USD Million) By Region

Figure 37: Global HDAC2 Antibody Market Share (%) By: Regions (2032)

Figure 38: Global HDAC2 Antibody Market Volume (K) By Region

Figure 39: Global HDAC2 Antibody Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

139 items

Table 1: Market Segmentation Analysis

Table 2: Global HDAC2 Antibody Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global HDAC2 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global HDAC2 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global HDAC2 Antibody Market Value (USD Million) By Region

Table 14: Global HDAC2 Antibody Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global HDAC2 Antibody Market Volume (K) By Region

Table 31: Global HDAC2 Antibody Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global HDAC2 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global HDAC2 Antibody Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global HDAC2 Antibody Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Thermo Fisher Scientific Basic Information And Sales Area

Table 52: Thermo Fisher Scientific. Products Portfolio

Table 53: Merck Basic Information And Sales Area

Table 54: Merck. Products Portfolio

Table 55: Boster Bio Basic Information And Sales Area

Table 56: Boster Bio. Products Portfolio

Table 57: Active Motif Basic Information And Sales Area

Table 58: Active Motif. Products Portfolio

Table 59: stjohnslabs Basic Information And Sales Area

Table 60: stjohnslabs. Products Portfolio

Table 61: Fortis Life Sciences Basic Information And Sales Area

Table 62: Fortis Life Sciences. Products Portfolio

Table 63: Proteintech Group Basic Information And Sales Area

Table 64: Proteintech Group. Products Portfolio

Table 65: Diagenode Basic Information And Sales Area

Table 66: Diagenode. Products Portfolio

Table 67: Abcepta Basic Information And Sales Area

Table 68: Abcepta. Products Portfolio

Table 69: Abclonal Basic Information And Sales Area

Table 70: Abclonal. Products Portfolio

Table 71: Cell Signaling Technology Basic Information And Sales Area

Table 72: Cell Signaling Technology. Products Portfolio

Table 73: LifeSpan BioSciences Basic Information And Sales Area

Table 74: LifeSpan BioSciences. Products Portfolio

Table 75: GeneTex Basic Information And Sales Area

Table 76: GeneTex. Products Portfolio

Table 77: Bioss Basic Information And Sales Area

Table 78: Bioss. Products Portfolio

Table 79: Abcam Basic Information And Sales Area

Table 80: Abcam. Products Portfolio

Table 81: Biorbyt Basic Information And Sales Area

Table 82: Biorbyt. Products Portfolio

Table 83: RayBiotech Basic Information And Sales Area

Table 84: RayBiotech. Products Portfolio

Table 85: NSJ Bioreagents Basic Information And Sales Area

Table 86: NSJ Bioreagents. Products Portfolio

Table 87: OriGene Technologies Basic Information And Sales Area

Table 88: OriGene Technologies. Products Portfolio

Table 89: Shanghai Biyuntian Biotechnology Basic Information And Sales Area

Table 90: Shanghai Biyuntian Biotechnology. Products Portfolio

Table 91: Jingjie PTM BioLab Basic Information And Sales Area

Table 92: Jingjie PTM BioLab. Products Portfolio

Table 93: Beijing Solarbio Basic Information And Sales Area

Table 94: Beijing Solarbio. Products Portfolio

Table 95: Global Market Value (USD Million) (2025-2032) By Type

Table 96: Global Market Share (%) By Type (2032)

Table 97: Global Market Value (USD Million) (2025-2032) By Application

Table 98: Global Market Share (%) By Application (2032)

Table 99: Global Market Volume (K) (2025-2032) By Type

Table 100: Global Market Share (%) By Type (2032)

Table 101: Global Market Volume (K) (2025-2032) By Application

Table 102: Global Market Share (%) By Application (2032)

Table 103: Global HDAC2 Antibody Market Value (USD Million) By Region

Table 104: Global HDAC2 Antibody Market Share (%) By Region (2025-2032)

Table 105: North America Market Value (USD Million) (2025-2032) By Country

Table 106: North America Market Value (USD Million) (2025-2032) By Type

Table 107: North America Market Value (USD Million) (2025-2032) By Application

Table 108: Europe Market Value (USD Million) (2025-2032) By Country

Table 109: Europe Market Value (USD Million) (2025-2032) By Type

Table 110: Europe Market Value (USD Million) (2025-2032) By Application

Table 111: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 112: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 113: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 114: South America Market Value (USD Million) (2025-2032) By Country

Table 115: South America Market Value (USD Million) (2025-2032) By Type

Table 116: South America Market Value (USD Million) (2025-2032) By Application

Table 117: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 118: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 119: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 120: Global HDAC2 Antibody Market Volume (K) By Region

Table 121: Global HDAC2 Antibody Market Share (%) By Region (2025-2032)

Table 122: North America Market Volume (K) (2025-2032) By Country

Table 123: North America Market Volume (K) (2025-2032) By Type

Table 124: North America Market Volume (K) (2025-2032) By Application

Table 125: Europe Market Volume (K) (2025-2032) By Country

Table 126: Europe Market Volume (K) (2025-2032) By Type

Table 127: Europe Market Volume (K) (2025-2032) By Application

Table 128: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 129: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 130: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 131: South America Market Volume (K) (2025-2032) By Country

Table 132: South America Market Volume (K) (2025-2032) By Type

Table 133: South America Market Volume (K) (2025-2032) By Application

Table 134: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 135: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 136: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 137: Research Programs/Design For This Report

Table 138: Key Data Information From Secondary Sources

Table 139: Key Data Information From Primary Sources

FAQs

1. What is the current global HDAC2 Antibody market size?

Latest estimates place the global HDAC2 Antibody market size at USD 145 million in 2023, driven by rising oncology and epigenetics research funding.

2. What is the forecasted growth rate through 2030?

Analysts project a 9.2% CAGR from 2024 to 2030, with the HDAC2 Antibody market size expected to reach USD 270 million by the end of the decade.

3. What are the primary growth drivers?

Surging demand for precision cancer diagnostics, expanding pharma R&D budgets, and increased publication volume on histone deacetylase signaling pathways fuel adoption.

4. Which factors challenge market expansion?

High antibody cross-reactivity failure rates, complex multi-step validation protocols, and reimbursement gaps for companion diagnostic tests restrain faster uptake.

5. Which regions lead consumption?

North America commands 42% share followed by Europe at 30%; Asia-Pacific is the fastest-growing region owing to government biotech incentives and CRO investments.

6. Who are the top companies competing?

Abcam, Thermo Fisher, Santa Cruz Biotechnology, Cell Signaling Technology, and Merck dominate through broad catalog portfolios and custom antibody services.

7. Where do future opportunities lie?

Multiplex IHC panels, recombinant monoclonal lines, and AI-guided epitope mapping present high-value openings, especially in immuno-oncology companion diagnostics.

8. How is technology impacting the market?

CRISPR-enabled knockout validation, single-cell western platforms, and recombinant rabbit antibody production are boosting specificity and cutting lot-to-lot variability.

9. What does the regulatory landscape look like?

FDA classifies HDAC2 Antibody-based kits as Class II IVDs in the U.S., while CE-IVDR certification in Europe now demands extensive clinical performance data for approval.

10. What is the long-term future outlook?

The future outlook remains bullish: integrated proteogenomics, personalized histone-modifier therapies, and liquid biopsy applications will widen revenue pools post-2030.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

HDAC2 Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	285.00 million
Revenue forecast in 2033	720.91 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; Merck; Boster Bio; Active Motif; stjohnslabs; Fortis Life Sciences; Proteintech Group; Diagenode; Abcepta; Abclonal; Cell Signaling Technology; LifeSpan BioSciences; GeneTex; Bioss; Abcam; Biorbyt; RayBiotech; NSJ Bioreagents; OriGene Technologies; Shanghai Biyuntian Biotechnology; Jingjie PTM BioLab; Beijing Solarbio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options